

ISSN 2757-8135



EUROPEAN  
**EYE**  
RESEARCH

Vol. 4 / No 3 / December 2024

[www.europeaneyeresearch.com](http://www.europeaneyeresearch.com)

**BRIMOLIX**  
Brimonidin Tartarat %0,15

**Latafree**  
Latanoprost

**Duosopt**  
Dorzolamid+Timolol

**PREZERVAN İÇERMEZ\***



Sağlık meslek mensupları için hazırlanmıştır.  
QR kodları okutarak sırasıyla BRIMOLIX, LATAFREE  
ve DUOSOPT kısa ürün bilgilerine ulaşabilirsiniz.



 **vem | OFTALMOLOJİ**

# KONFORUN<sup>1-3</sup>

Nemin<sup>1</sup>

Görüşün<sup>2</sup>

Nefes Alabilirliğin<sup>3</sup>

Hafifliğin<sup>2,4,5</sup>

## ÖTESİNE GEÇİN!



**BAUSCH + LOMB**

# Adrussen PLUS

İÇERİK	MİKTAR
<b>Astaksantin</b>	<b>4 mg</b>
Lutein	10 mg
Zeaksantin	2 mg
EPA	185 mg
DHA	140 mg
C Vitamini	60 mg
E Vitamini	30 mg
Çinko	12,5 mg
Bakır	1 mg



# YENİ ENDİKASYONLARDA LUCENTIS®'İN GÜVEN VEREN GÜCÜ<sup>1-9</sup>



TÜRKİYE'DE  
RETİNA ALANINDA  
**EN GENİŞ**  
ENDİKASYONA SAHİP  
anti-VEGF<sup>6</sup>

VEGF: Vasküler endotelial büyüme faktörü; nYBMD: Neovasküler (yaş tıp) yaşa bağlı makula dejenerasyonu; DMÖ: Diyabetik maküler ödem; RVT: Retinal ven tıkanıklığı; PM'ye bağlı KNV: Patolojik miyopiye bağlı KNV; PDR: Proliferatif diyabetik retinopati; KNV: Koroidal neovaskülarizasyon; ROP: Prematüre retinopatisi. ROP endikasyonu, flakonda mevcuttur. Detaylı bilgi için Kısa Ürün Bilgisine ulaşabilirsiniz.

**Referanslar:** 1. Campochiaro PA, et al. Ophthalmology. 2010;117(6):1102-1112.e1. 2. Brown DM, et al. Ophthalmology. 2010;117(6):1124-1133.e1. 3. Rosenfeld PJ, et al. The New England Journal of Medicine. 2006;355(14):1419-1431. 4. Nguyen QD, et al. Ophthalmology 2012;119(4):789-801. 5. Wolf S, et al. Ophthalmology. 2014;121(3):682-92.e2. 6. LUCENTIS® Kısa Ürün Bilgisi. 7. Gross JG, et al. JAMA. 2015;314(20):2137-2146. 8. Lai TYY, et al. Retina. 2018;38(8):1464-1477. 9. Stahl A, et al. Lancet. 2019;394(10208):1551-1559.

Detaylı bilgi için LUCENTIS® Kısa Ürün Bilgisine <https://www.novartis.com.tr/product-list> adresinden ulaşabilirsiniz. Reçete ile satılır. Ürünlerimizin fiyatları TITCK tarafından belirlenerek [www.titck.gov.tr](http://www.titck.gov.tr) adresinde yayımlanmaktadır. Güncel bilgilere erişmek için firmamıza başurunuz.



ISSN - 2757-8135

EUROPEAN  
**EYE**  
RESEARCH

### EDITOR-IN-CHIEF

**Filiz Afrashi, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

### ASSOCIATE EDITORS

**Cezmi Akkin, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

**Melis Palamar, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

**Suzan Guven Yilmaz, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

**Elif Demirkilinc Biler, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

**Cumali Degirmenci, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

### INTERNATIONAL ADVISORY BOARD

**Iqbal Ike Ahmed, MD**

University of Toronto, Ophthalmology,  
Toronto, Canada

**Jose Fernando Arevalo, MD, PhD**

Johns Hopkins Bayview Medical Center, Ophthalmology,  
Baltimore, USA

**Carl Claes, MD**

Claes Retina Clinic, Ophthalmology, Antwerp, Belgium

**Murat Dogru, MD**

Keio University, Ophthalmology, Tokyo, Japan

**Matrin Litev, MD**

"St. Petka" Eye Clinic, Varna, Bulgaria

**Gueorgui Markov, MD, PhD**

Sofia University Faculty of Medicine, Ophthalmology, Sofia,  
Bulgaria

**Arman Mashayekhi, MD**

Mayo Clinic, Ophthalmology, Jacksonville, Miami, USA

**Miguel Angel Materin, MD, PhD**

Duke University School of Medicine, Ophthalmology, North  
Carolina, USA

**Gulgun Tezel, MD**

Columbia University, Ophthalmology, New York, USA

**Tongalp Tezel, MD**

Columbia University, Ophthalmology, New York, USA

### LANGUAGE EDITOR

**Melis Palamar, MD**

Ege University Faculty of Medicine, Ophthalmology, Izmir, Türkiye

### STATISTICS EDITOR

**Kivanc Yuksel, PhD**

Ege University Faculty of Medicine, Biostatistics and Medical Informatics, Izmir, Türkiye

**The European Eye Research is indexed in OUCI, Scilit, Scope Database, EBSCO, TR Dizin, Gale Cengage, Sherpa Romeo, Worldcat, Asian Science Citation Index (ASCI), Ideal Online and DOAJ.**

#### Owner

Melis Palamar, MD

Ege Universitesi Tip Fakultesi, Goz Hastaliklari AD, Bornova, Izmir, Türkiye  
Tel: +90 232 390 37 88  
melispalamar@gmail.com

#### Editor

Filiz Afrashi, MD

Ege Universitesi Tip Fakultesi, Goz Hastaliklari AD, Bornova, Izmir, Türkiye  
Tel: +90 232 390 37 88  
afrashif@yahoo.com

Contact:

Publisher



Goztepe Mah. Fahrettin Kerim Gokay Cad. No: 200 Da: 2, Goztepe, Kadikoy, Istanbul, Türkiye  
Phone: +90-216-550 61 11 Fax: +90-216-550 61 12  
e-mail: kare@karepb.com Web: kare@karepb.com

Publications Coordinator: Eymen Iskender  
Graphic Design: Beste Kurtcu

Owned by on behalf of the Director of European Eye Research, Istanbul: Melis PALAMAR | Executive Editor: Filiz AFRASHI | Publication Type: Periodical | Printed: Yıldırım  
Matbaacılık +90 212 629 80 37 | Printing Date: December 2024

**The European Eye Research is indexed in EBSCO, TUBITAK TR Index, Gale Cengage, Directory of Open Access Journals (DOAJ), Asian Science Citation Index (ASCI), Open Ukrainian Citation Index (OUCI), Scilit, Scope Database, Sherpa Romeo, Worldcat and Ideal Online.**



## NATIONAL ADVISORY BOARD

### **Yasemin Akcay, MD**

Ege University Faculty of Medicine, Medical Biochemistry, İzmir, Türkiye

### **Zuleyha Yalniz Akkaya, MD**

Ankara Research and Training Hospital, Ophthalmology, Ankara, Türkiye

### **Zeynep Aktas, MD**

Gazi University Faculty of Medicine, Ophthalmology, Ankara, Türkiye

### **Gul Arikan, MD**

Dokuz Eylul University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Halil Ates, MD**

Private Practice, Ophthalmology, İzmir, Türkiye

### **Mine Esen Baris, MD**

Ege University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Cenk Can, MD**

Ege University Faculty of Medicine, Pharmacology, İzmir, Türkiye

### **Naim Ceylan, MD**

Ege University Faculty of Medicine, Radiology, İzmir, Türkiye

### **Cagatay Caglar, MD**

Hitit University Faculty of Medicine, Ophthalmology, Corum, Türkiye

### **Mehmet Citirik, MD**

Ulucanlar Research and Training Hospital, Ophthalmology, Ankara, Türkiye

### **Sibel Demirel, MD**

Ankara University Faculty of Medicine, Ophthalmology, Ankara, Türkiye

### **Oya Donmez, MD**

Izmir Tinaztepe University, Ophthalmology, İzmir, Türkiye

### **Sema Oruc Dundar, MD**

Adnan Menderes University Faculty of Medicine, Ophthalmology,  
Aydın, Türkiye

### **Sait Egrilmez, MD**

Private Practice, Ophthalmology, İzmir, Türkiye

### **Sinan Emre, MD**

Ekol Eye Hospital, Ophthalmology, İzmir, Türkiye

### **Muhsin Eraslan, MD**

Marmara University Faculty of Medicine, Ophthalmology, İstanbul, Türkiye

### **Korhan Fazil, MD**

Beyoglu Eye Research and Training Hospital, Ophthalmology, İstanbul, Türkiye

### **Sirel Gur Gungor, MD**

Baskent University Faculty of Medicine, Ophthalmology, Ankara, Türkiye

### **Murat Hasanreisoglu, MD**

Koc University Faculty of Medicine, Ophthalmology, İstanbul, Türkiye

### **Sibel Kadayifcilar, MD**

Hacettepe University Faculty of Medicine, Ophthalmology, Ankara, Türkiye

### **Mahmut Kaya, MD**

Dokuz Eylul University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Ozcan Kayikcioglu, MD**

Celal Bayar University Faculty of Medicine, Ophthalmology, Manisa, Türkiye

### **Tolga Kocaturk, MD**

Adnan Menderes University Faculty of Medicine, Ophthalmology,  
Aydın, Türkiye

### **Bengu Ekinci Koktekir, MD**

Selcuk University Faculty of Medicine, Ophthalmology, Konya, Türkiye

### **Tuncay Kusbeci, MD**

Bozyaka Research and Training Hospital, Ophthalmology, İzmir, Türkiye

### **Jale Mentec, MD**

Ege University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Serhad Nalcaci, MD**

Ege University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Huseyin Onay, MD**

Multigen Genetic Diseases Assessment Center, Medical Genetics,  
İzmir, Türkiye

### **Altan Atakan Ozcan, MD**

Cukurova University Faculty of Medicine, Ophthalmology, Adana, Türkiye

### **Taylan Ozturk, MD**

Dokuz Eylul University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Gozde Sahin, MD**

Balıkesir University Faculty of Medicine, Ophthalmology, Balıkesir, Türkiye

### **Ali Osman Saatci, MD**

Dokuz Eylul University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Ozlem Barut Selver, MD**

Ege University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Hande Taylan Sekeroglu, MD**

Hacettepe University Faculty of Medicine, Ophthalmology, Ankara, Türkiye

### **Huseyin Cem Simsek, MD**

Mugla Sitki Kocman University Faculty of Medicine, Ophthalmology,  
Mugla, Türkiye

### **Didar Ucar, MD**

Cerrahpasa University Faculty of Medicine, Ophthalmology, İstanbul,  
Türkiye

### **Onder Uretmen, MD**

Ege University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Canan Aslı Utine, MD**

Dokuz Eylul University Faculty of Medicine, Ophthalmology, İzmir, Türkiye

### **Ayşe Yagci, MD**

Private Practice, Ophthalmology, İzmir, Türkiye

### **Banu Yaman, MD**

Ege University Faculty of Medicine, Medical Pathology, İzmir, Türkiye

### **Yusuf Yildirim, MD**

Beyoglu Eye Research and Training Hospital, Ophthalmology,  
İstanbul, Türkiye

### **Mehmet Ozgur Zengin, MD**

Izmir Katip Celebi University, Ophthalmology, İzmir, Türkiye



## INFORMATION FOR THE AUTHORS

European Eye Research is an international, scientific, open access periodical published in accordance with independent, unbiased, and double-blind peer-review principles. Three issues are released every year in April, August, and December. The publication language of the journal is English.

European Eye Research aims to contribute to the international literature by publishing high-quality manuscripts in the field of ophthalmology. The target audience includes specialists and physicians-in-training in all branches of ophthalmology.

### REVIEW PROCESS

Manuscripts submitted to European Eye Research will undergo a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation process of manuscripts submitted by editors or by members of the editorial board. The editor is the final authority in the decision-making process for all submissions. The review is typically completed within one month of submission to the journal. Authors will be sent constructive reviewer comments intended to be useful. In general, the instructions, objections, and requests made by the reviewers should be followed. The revised manuscript should clearly and precisely indicate every step taken in accordance with the reviewers' notes. A list of responses and the corrections made to each comment should be provided.

### ETHICS

Studies using human or animal subjects should be approved by the appropriate institutional and local Ministry of Health ethics committees. Ethics approval of research protocols in accordance with international agreements (World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects," amended in October 2013, [www.wma.net](http://www.wma.net)) is required for experimental, clinical, and drug studies, as well as for some case reports. Ethics committee reports or an equivalent official document may be requested from the authors. For manuscripts involving experimental research on humans, a statement should be included that shows that written, informed consent of patients and volunteers was obtained. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. A statement regarding patient consent, and the name of the ethics committee, the ethics committee approval date, and number should be stated in the Materials and Methods section of the manuscript. It is the authors' responsibility to carefully protect patients' anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or of their legal representative should be enclosed.

### AUTHORSHIP

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - [www.icmje.org](http://www.icmje.org)). The ICMJE recommends that authorship should be based on the following 4 criteria:

- Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for their own work, authors should have

confidence in the integrity of the contributions of their co-authors and each author should be able to identify which co-authors are responsible for other parts of the work.

All of those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who provided a contribution but do not meet all four criteria should be recognized separately on the title page and in the Acknowledgements section at the conclusion of the manuscript.

European Eye Research requires that corresponding authors submit a signed and scanned version of the authorship contribution form (available for download through [www.europeaneyeresearch.com](http://www.europeaneyeresearch.com)) during the initial submission process in order to appropriately indicate and observe authorship rights and to prevent ghost or honorary authorship. Please note that the list of authors on the final manuscript will be presented in the order provided on this form. If the editorial board suspects a case of "gift authorship," the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding author should also send a short statement declaring that they accept all responsibility for authorship during the submission and review stages of the manuscript.

### ORCID

The Open Researcher and Contributor ID (ORCID) number of each author must be submitted when creating an account for correspondence. To obtain an ORCID number, please visit <https://orcid.org/>.

### PLAGIARISM DETECTION

All submissions are screened using similarity detection software at least two times: on submission and after completing revisions. In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, or data falsification/fabrication, the editorial board will follow and act in accordance with COPE guidelines. Plagiarism, including self-plagiarism, that is identified at any stage will result in rejection of the manuscript.

### Publication Charges

This journal assesses no submission fees, publication fees, or page charges.

### MANUSCRIPT PREPARATION

Manuscripts should be prepared in accordance with the ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2015 - <http://www.icmje.org/icmje-recommendations.pdf>). Authors are required to prepare manuscripts in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines for randomized research studies, the STrengthening the Reporting of OBServational studies in Epidemiology (STROBE) guidelines for observational original research studies, the Standards for Reporting Diagnostic Accuracy (STARD) guidelines, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for experimental animal studies, and the Transparent Reporting of Evaluations with Non-randomized Designs (TREND) guidelines for non-randomized behavioral and public health evaluations.

Manuscripts may only be submitted through the journal's online manuscript submission and evaluation system, <http://jag.journalagent.com>. Manuscripts submitted via any other medium will not be evaluated.

Manuscripts will first be submitted to a technical evaluation process in which the editorial staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the author with requests for technical correction.



## Artificial Intelligence (AI)-Assisted Technology

At submission, the journal should require authors to disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Authors who use such technology should describe, in both the cover letter and the submitted work, how they used it. Use of AI for writing assistance should be reported in the acknowledgment section. Authors who used AI technology to conduct the study should describe its use in the methods section in sufficient detail to enable replication to the approach, including the tool used, version, and prompts where applicable. Chatbots (such as ChatGPT) should not be listed as authors because they cannot be responsible for the accuracy, integrity, and originality of the work, and these responsibilities are required for authorship. Therefore, humans are responsible for any submitted material that included the use of AI-assisted technologies. Authors should carefully review and edit the result because AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Authors should not list AI and AI-assisted technologies as an author or co-author, nor cite AI as an author. Authors should be able to assert that there is no plagiarism in their paper, including in text and images produced by the AI. Humans must ensure there is appropriate attribution of all quoted material, including full citations.

The quality and clarity of the language used in a manuscript are very important. The editors may request that authors have the manuscript professionally edited if the language of the submission does not conform to the journal standards. European Eye Research uses American English. Please submit text of a quality ready for publication. It is also requested that authors observe the specific formatting requirements noted in the submission checklist and elsewhere in these instructions. For information about language editing and copyediting services, authors may contact Kare Publishing at [kare@karepb.com](mailto:kare@karepb.com).

## MANUSCRIPT TYPES

**Original Article:** This is the most valued type of article, since it provides new information based on original research. The main text of an original article should be structured with Introduction, Methods, Results, Discussion, and Conclusion subheadings. Original articles are limited to 3500 words and 30 references.

**Editorial Comment:** Editorial comments provide a brief critical commentary offered by reviewers with experience and standing in the topic of a research article previously published in the journal. The authors are selected and invited by the journal to provide the benefit of their expertise. The submission should not include an abstract, keywords, tables, figures, or images. The word count is limited to 1000 and 10 references may be included.

**Review Article:** Two kinds of review are accepted for publication in European Eye Research: narrative review and systematic review. Reviews of relevant topics not recently discussed in this format that will be helpful to readers are welcomed.

**Case Report:** There is limited space for case reports and therefore the journal selects reports of rare cases or conditions that reflect challenges in diagnosis and treatment, those offering new therapies or revealing knowledge not described in the literature, or presenting something otherwise particularly interesting and educative. The abstract should be structured with a background, brief case description, and conclusion, and is limited to 150 words. The report must include the subheadings of introduction, case report, and discussion, which includes a conclusion. A case report is limited to 1000 words and 10 references.

**Letter to the Editor:** This type of manuscript discusses important observations, overlooked aspects, or details lacking in a previously published article. Noteworthy articles on subjects within the scope of the journal, particularly educative cases, may also be submitted in the form of a "Letter to the editor." No abstract, keywords, tables, figures, images, or other media should be included. The article that is the subject of commentary must be properly cited within the manuscript. The text should be unstructured and is limited to 500 words. No more than 5 references will be accepted.

**Cover Letter:** The cover letter should include the article title, article type, and the full name of the corresponding author and a statement declaring the absence or presence of any conflict of interest. The corresponding author should briefly summarize the paper and affirm that it has not already been published, accepted, or is under simultaneous review for publication elsewhere. It should be stated that if the manuscript is accepted by European Eye Research, the paper will not be published elsewhere in the same form,

in English or in any other language.

**Title Page:** A separate title page should be submitted with all submissions and this page should include:

- The full title of the manuscript as well as a short title (running head) of no more than 50 characters;
- Name, affiliation, ORCID ID number, and highest academic degree of the author(s);
- Funding and other material support;
- Name, address, phone number(s), fax number, and e-mail address of the corresponding author;
- Acknowledgement of individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria; and
- The name, date and place of manuscripts that have been presented orally or as a poster at a conference or other event.

**Abstract:** An English-language abstract is required with all submissions except editorial comments, images, and letters to the editor. Systematic reviews and original articles should contain a structured abstract of maximum 250 words with the subheadings of objective, methods, results, and conclusion.

**Keywords:** Each submission must be accompanied by a minimum of three and a maximum of six keywords for subject indexing included at the end of the abstract. The keywords should be listed in full without abbreviations and should be separated by commas. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (<https://www.nlm.nih.gov/mesh/MBrowser.html>).

**Tables:** Tables should be uploaded as separate files and not embedded in the main text. They should be numbered consecutively in the order they are referred to within the main text. A descriptive title must be placed above the tables. Abbreviations used in the tables should be defined below the table with footnotes, even if they are defined within the main text. Tables should be created using the "insert table" command of the word processing software used, and they should be designed for easy reading. Data presented in tables should not be a repetition of the data presented within the main text but should support the main text.

**Figures and Figure Legends:** Figures, graphics, and photographs should be submitted as separate files in TIFF or JPEG format through the article submission system. The files should not be embedded in a Word document or the main document. When there are figure subunits, the subunits should not be combined to form a single image. Each subunit should be submitted separately through the submission system and labeled appropriately, not merely a, b, c, etc. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks may be used in the images to clarify the figure legend. Like the rest of the submission, figures should be blinded. Any information within the images that may identify an individual or institution should be protected. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100x100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition. Units should be prepared in accordance with the International System of Units (SI). When a drug, device, hardware, or software program, or other product is mentioned within the main text, the name of the product, the manufacturer/copyright holder of the product (not simply the vendor), and the city and the country of the company (including the state, if in USA or otherwise appropriate), should be provided in parentheses in the following format: "Discovery St PET/CT scanner (General Electric Co., Boston, MA, USA)."

All references, tables, and figures should be referred to within the main text in consecutive order, and they should be numbered in the same order in the additional file submissions.

Limitations, drawbacks, and shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

**References:** The editorial team requests that the authors cite related recently published articles (preferably within the last 10 years) in their manuscripts, with the exception of historical papers.

If an ahead-of-print publication is cited, the digital object identifier (DOI) number should be provided. Authors are responsible for the accuracy of references.

Journal titles should be abbreviated in accordance with the journal abbreviations in the Index Medicus /MEDLINE/ PubMed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first three should be listed followed by "et al." In the main text of the manuscript, references should be cited using superscript Arabic numerals. The reference styles for different types of publications are presented in the following examples.

*Journal article:* Wang H, Cheng JW, Wei RL, Cai JP, Li Y, Ma XY. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. *Can J Ophthalmol* 2013;48:186–92.

*Epub ahead-of-print article:* Cai L, Yeh BM, Westphalen AC, Roberts JP, Wang ZJ. Adult living donor liver imaging. *Diagn Interv Radiol* 2016 Feb 24. doi: 10.5152/dir.2016.15323. [Epub ahead-of-print].

*Manuscript published in electronic format:* Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* (serial online) 1995 Jan-Mar (cited 1996 June 5): 1(1): (24 screens). Available from: URL: <http://www.cdc.gov/ncidod/EID/cid.htm>.

*Book section:* Suh KN, Keystone JS. Malaria and babesiosis. Gorbach SL, Bartlett JG, Blacklow NR, editors. *Infectious Diseases*. Philadelphia: Lippincott Williams; 2004.p.2290-308.

*Books with a single author:* Sweetman SC. *Martindale the Complete Drug Reference*. 34th ed. London: Pharmaceutical Press; 2005.

*Editor(s) as author:* Huizing EH, de Groot JAM, editors. *Functional reconstructive nasal surgery*. Stuttgart-New York: Thieme; 2003.

*Conference proceedings:* Bengissson S, Sothemin BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors. *MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics*; 1992 Sept 6-10; Geneva, Switzerland. Amsterdam: North-Holland; 1992. pp.1561-5.

*Scientific or technical report:* Cusick M, Chew EY, Hoogwerf B, et al. Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS). *Early Treatment Diabetic Retinopathy Study Kidney Int*: 2004. Report No: 26.

## REVISIONS

When submitting a revised version of a paper (include a clean copy and a highlighted copy), the author must submit a detailed response to the reviewers that replies to each issue raised by the reviewers and indicates where changes can be found (each reviewer's comment, followed by the author's reply and line number where changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be withdrawn. If the submitting author(s) believe that additional time is required, they should request this extension within the initial 30-day period.

Accepted manuscripts are copy edited for grammar, punctuation, format, and clarity. Manuscripts will be published online on the journal's webpage as an ahead-of-print version during the completion of the publication process and included in the scheduled issue. A PDF proof of the manuscript will be sent to the corresponding author and publication approval is requested within 2 days of receipt.

## PUBLICATION PROCESS

Accepted manuscripts will be made available and citable online as rapidly as possible. The stages of publication are as follows:

*Uncorrected publication:* A PDF of the final, accepted (but unedited and uncorrected) paper will be published online on the journal web page under the "Accepted Articles" section. A DOI will be assigned to the article at this stage.

*Ahead-of-print publication:* After copy editing, typesetting, and review of the resulting proof, the final corrected version will be added online in the "Ahead-of-Print" section.

*Final publication:* The final, corrected version will appear in an issue of the journal and will be added to the journal website. To ensure rapid publication, we ask authors to provide their publication approval during the proof-reading process as quickly as possible, and return corrections within 48 hours of receiving the proof.

## SUBMISSION CHECKLIST

Please use this list and the following explanations to prepare your manuscript and perform a final check before submission to ensure a timely review.

## Formatting of text

- Format your document as A4 paper, use double line spacing, Times font size 12, and do not justify the right margin;
- Main headings and subheadings should be in 12-point and bold font;
- Type a single space at the end of each sentence;
- Do not use bold face for emphasis within the text;
- Numbers one to ten are written out in words unless they are used as a unit of measurement, except in figures and tables;
- Use a single hard return to separate paragraphs. Do not use tabs or indents to start a paragraph;
- Do not use software options for hyphenation, headers, or footers;
- Use page numbering;
- Use line numbers; and
- Use US English.

## Include the following items:

### Cover letter

#### Title page including:

- Article type;
- Article title;
- Running title;
- All author names, affiliations, and ORCID ID numbers;
- The author designated as the corresponding author with contact details
  - Full postal address, phone number(s), and e-mail address;
- Acknowledgements;
- Manuscripts that have been presented orally or as a poster must include the name of the event, the date, and the location;
- Government or other financial support for the study; and
- Word count
  - Abstract word count
  - Text word count.

#### Main text of the manuscript must include (ensure written according to journal rules):

- Article title,
- Abstract,
- Keywords,
- Text with required subheadings,
- References, and
- Figures and tables.
- Numbered according to text citation
- Descriptive legends/titles and abbreviations
- Ensure all figure and table citations in the text match the files provided
- **Figures:** submitted separately and appropriately labeled
- **Tables:** submitted separately and appropriately labeled
- **Ensure that ALL of the following forms have been properly completed and submitted:**
  - ICMJE Potential Conflict of Interest Disclosure Form (completed by all contributing authors),
  - Copyright Transfer Form, and
  - Author Contributions Form.

These forms are available for download at <http://europeaneyeresearch.com>

## Further review

- Check the statistical analysis for full and accurate description;
- Use US English spell check and grammar check software functions;
- Check that all references cited in the text are correctly listed in the reference list;
- Permission has been obtained for use of copyrighted material from other sources (including the Internet);
- All abbreviations have been identified; and
- Compliance with all of the journal policies detailed in this guide.



## CONTENTS

Editorial ..... VII

### ORIGINAL ARTICLES

**Comparison of intraocular pressure measurement using Goldmann, tonopen, and non-contact tonometers in patients with penetrating keratoplasty**  
*Binzet M, Kusbeci T, Arcagok HM, Yuksel B* ..... 175–180

**Association of diabetic neuropathy with contrast sensitivity impairment and OCT parameters in type-2 diabetic patients without retinopathy**  
*Kahraman HG, Aydin E, Guven YZ, Boluk E, Kurt Incesu T* ..... 181–186

**Evaluation of hypercoagulability in ocular vascular pathologies**  
*Koseoglu ND, Turgut Cosan D, Musmul A, Ozer A* ..... 187–192

**Investigation of subtypes of diabetic macular edema refractory to anti-VEGF treated with a single-dose dexamethasone implant**  
*Ismayilov AS, Kahkeci B, Kargin AM, Ulusoy MO* ..... 193–201

**An evaluation of quality and usefulness of information on YouTube videos about pterygium and its treatment**  
*Azizagaoglu B, Asena L, Dursun Altinors D* ..... 202–208

**Quantitative assessment of the parafoveal vessel density and ganglion cell inner plexiform layer thickness in non-proliferative macular telangiectasia type 2**  
*Karalezli A, Kaya C, Kaderli S, Kaderli A, Sul S* ..... 209–216

**Selective serotonin reuptake inhibitors and ocular health: Analyzing retinal and choroidal thickness variations**  
*Yilmaz IE, Er KE, Kara N* ..... 217–222

**Effects of blood HbA1c and mean platelet volume levels in diabetic macular edema patients who received dexamethasone implant**  
*Alyoruk F, Arican E, Turgut B, Ersan I, Erdogan H, Torun S* ..... 223–227

### CASE REPORTS

***Thelazia* eye infection: The first human case in Türkiye**  
*Isbilir A, Ozkoc S, Yilmaz E, Utine CA* ..... 228–232

**Presumed acute unilateral toxoplasma papillitis without vitritis: A case report**  
*Aktas K, Canleblebici M, Balbaba M, Yildirim H* ..... 233–236

### REVIEW

**Current biosimilar anti-VEGF drugs in retinal diseases**  
*Sensoy E, Citirik M* ..... 237–244



## EDITORIAL

Dear Colleagues,

Here we come to the end of another year with the 4<sup>th</sup> volume, 3<sup>rd</sup> issue of *European Eye Research*, including 8 original articles, 2 case reports, and a review.

In the present issue, 6 articles mainly focus on the retina. Diabetic complications, including retinopathy, maculopathy, and neuropathy, are the main topics.

One article evaluates the most reliable intraocular measurement techniques in penetrating keratoplasty cases.

Finally, one original article addresses an interesting and relatively new topic: "An Evaluation of the Quality and Usefulness of Information on YouTube Videos About Pterygium and Its Treatment."

As case reports, we have two parasitic infections: Toxoplasma and Thelazia.

The review in the present issue discusses current biosimilar anti-VEGF drugs in retinal diseases, offering an enlightening perspective.

We hope you enjoy reading and sharing this issue.

*European Eye Research* is proud to rise with you—the readers, the valuable writers, the dedicated reviewers, and everyone who brings life to ophthalmology.

We wish you a happy new year filled with health, luck, success, and love.

Melis Palamar, MD